These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36539267)

  • 1. Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study.
    Smith KA; Piehl F; Olsson T; Alfredsson L; Hillert J; Kockum I; Stridh P; Montgomery S
    J Neurol Neurosurg Psychiatry; 2023 May; 94(5):337-348. PubMed ID: 36539267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the impact of intrathecal baclofen on the walking ability of people with Multiple Sclerosis related spasticity.
    Sammaraiee Y; Stevenson VL; Keenan E; Buchanan K; Lee H; Padilla H; Farrell RA
    Mult Scler Relat Disord; 2020 Nov; 46():102503. PubMed ID: 33032053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the cognitive benefits of intrathecal baclofen pump implantation in people with intractable multiple sclerosis related spasticity.
    Farrell R; Summers M; Doogan C; Mulhert N; Keenan E; Buchanan K; Lee H; Padilla H; Stevenson VL
    Mult Scler Relat Disord; 2021 May; 50():102831. PubMed ID: 33618123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
    Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spasticity in multiple sclerosis.
    Barnes MP; Kent RM; Semlyen JK; McMullen KM
    Neurorehabil Neural Repair; 2003 Mar; 17(1):66-70. PubMed ID: 12645447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal baclofen for multiple sclerosis related spasticity: A twenty year experience.
    Sammaraiee Y; Yardley M; Keenan L; Buchanan K; Stevenson V; Farrell R
    Mult Scler Relat Disord; 2019 Jan; 27():95-100. PubMed ID: 30366276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up.
    Rekand T; Grønning M
    J Rehabil Med; 2011 May; 43(6):511-4. PubMed ID: 21533331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.
    Stampacchia G; Gerini A; Mazzoleni S
    NeuroRehabilitation; 2016 Apr; 38(4):385-93. PubMed ID: 27061166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
    Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients.
    Ben Smail D; Peskine A; Roche N; Mailhan L; Thiébaut I; Bussel B
    Mult Scler; 2006 Feb; 12(1):101-3. PubMed ID: 16459726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
    Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ;
    Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments for spasticity and pain in multiple sclerosis: a systematic review.
    Beard S; Hunn A; Wight J
    Health Technol Assess; 2003; 7(40):iii, ix-x, 1-111. PubMed ID: 14636486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of baclofen in treatment of spasticity in multiple sclerosis.
    Sawa GM; Paty DW
    Can J Neurol Sci; 1979 Aug; 6(3):351-4. PubMed ID: 385132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study.
    Moccia M; Frau J; Carotenuto A; Butera C; Coghe G; Barbero P; Frontoni M; Groppo E; Giovannelli M; Del Carro U; Inglese C; Frasson E; Castagna A; Buccafusca M; Latino P; Nascimbene C; Romano M; Liotti V; Lanfranchi S; Rapisarda L; Lori S; Esposito M; Maggi L; Petracca M; Lo Fermo S; Altavista MC; Bono F; Eleopra R; Brescia Morra V
    Neurol Sci; 2020 Oct; 41(10):2781-2792. PubMed ID: 32281038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.